Effects of cholinergic modulation on serum insulin-like growth factor-I and its binding proteins in normal and diabetic subjects

Clinical Endocrinology
I S IsmailJ R Peters

Abstract

We wished to study alterations in serum insulin-like growth factor-I (IGF-I) and its binding proteins in subjects with insulin dependent diabetes mellitus (IDDM) and possible relations with metabolic and GH secretory status, before and after cholinergic modulation. In addition, we have investigated whether cholinergic modulation exerts any effects on IGF-I secretion, independently of any actions on GH secretory status. All subjects received GH releasing hormone (GHRH) 1-44; 80 micrograms i.v.) alone and 60 minutes following 120 mg of pyridostigmine orally or 200 mg of pierenzepine orally. The three tests were carried out in random order at least one week apart. Blood was sampled at 15-minute intervals over 120 minutes. Twelve male subjects with IDDM and no clinical evidence of complications were selected on the basis of HbA1 levels to provide a wide range of metabolic control. Six normal male subjects were also studied. Serum IGF-I, IGF-binding protein 1 (IGFBP-1) and IGFBP-3 were measured at regular intervals throughout the study. Fasting plasma glucose and HbA1 were measured before each study to provide measures of metabolic control. Serum IGF-I and IGFBP-3 levels were significantly lower while serum IGFBP-I levels were signi...Continue Reading

References

Aug 1, 1990·Diabetic Medicine : a Journal of the British Diabetic Association·J M HollyJ A Wass
Nov 1, 1991·The Journal of Clinical Endocrinology and Metabolism·J A BatchG Werther
Dec 1, 1986·The Journal of Clinical Investigation·R C Baxter, J L Martin
Sep 1, 1987·The Journal of Clinical Endocrinology and Metabolism·R C Baxter, C T Cowell
Feb 1, 1988·The Journal of Clinical Endocrinology and Metabolism·A M SuikkariM Seppälä
Sep 1, 1988·Journal of Endocrinological Investigation·K BrismarK Hall
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·J ZapfE R Froesch
Jan 1, 1988·Clinical Endocrinology·C DieguezM F Scanlon
Sep 1, 1988·The Journal of Endocrinology·J M HollyJ A Wass
Sep 1, 1986·The Journal of Clinical Endocrinology and Metabolism·K Tan, R C Baxter
Aug 1, 1970·The Journal of Clinical Investigation·A P Hansen
May 1, 1980·Diabetes·J T HayfordR G Thompson
Dec 1, 1981·The Journal of Clinical Endocrinology and Metabolism·J M HornerR L Hintz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.